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Kaposi's sarcoma-associated herpesvirus (KSHV) is the major biological cofactor contributing to development of Kaposi's sarcoma. KSHV
establishes a latent infection in human B cells expressing the latency-associated nuclear antigen (LANA), a critical factor in the regulation of viral
latency. LANA is known to modulate viral and cellular gene expression. We report here on some initial proteomic studies to identify cellular
proteins associated with the amino and carboxy-terminal domains of LANA. The results of these studies show an association of known cellular
proteins which support LANA functions and have identified additional LANA-associated proteins. These results provide new evidence for
complexes involving LANAwith a number of previously unreported functional classes of proteins including DNA polymerase, RNA helicase and
cell cycle control proteins. The results also indicate that the amino terminus of LANA can interact with its carboxy-terminal domain. This
interaction is potentially important for facilitating associations with other cell cycle regulatory proteins which include CENP-F identified in
association with both the amino and carboxy-termini. These novel associations add to the diversity of LANA functions in relation to the
maintenance of latency and subsequent transformation of KSHV infected cells.
© 2007 Elsevier Inc. All rights reserved.Keywords: Proteomics; Latency-associated nuclear antigen; KSHVIntroduction
Approximately 15% of cancers (about 1.5 million cases
per year, worldwide) have been attributed to viral (11%),
bacterial (4%) and other pathogens (0.1%) (Gencer et al.,
2003; O'Brien et al., 2003; Rosenblatt et al., 2003; Somech et
al., 2003). Infectious agents that cause cancer are also known
to persist for long periods in the host. How the host responds
to the infectious agents and how the agent modulates this
response is critical in allowing for its persistence and may
determine the risk of cancer (Srivastava et al., 2005). In
addition, oncogenic viruses in many cases have learned to
evade the immune system and such evasion strategies likely
contribute to their oncogenic potential. Therefore, the
immunobiology of persistent infections and in particular⁎ Corresponding author. Fax: +1 215 898 9557.
E-mail address: erle@mail.med.upenn.edu (E.S. Robertson).
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doi:10.1016/j.virol.2007.03.010those that lead to cancer must be better understood
(Srivastava et al., 2005). Studying viral–host protein interac-
tion in infected cells can provide new information on these
various strategies. The application of proteomics technology
to identify cellular proteins that can interact with viral
antigens in the infected host during latency, can lead us to
explore the specific viral–host protein interactions which
contribute to oncogenesis.
Kaposi's sarcoma-associated herpesvirus (KSHV), also
known as human herpesvirus 8 (HHV-8), has been linked to
several malignancies in humans (Cesarman et al., 1995a).
KSHV is the etiologic agent associated with development of
Kaposi's sarcoma (KS), primary effusion lymphoma (PEL)
and multicentric Castleman's disease (MCD) (Moore and
Chang, 2003). KSHV is a double-stranded DNA virus
classified as a gammaherpesvirus also called human herpes-
virus type 8 (HHV-8) and is the only known human γ2-
herpesvirus (Rhadinovirus) and the most recently discovered
318 R. Kaul et al. / Virology 364 (2007) 317–329human tumor virus (Chang et al., 1994). Like other members
of the herpesvirus family, KSHV/HHV-8 tightly regulates
expression of its genes. These genes can be divided in two
groups: those involved in latent infection, which facilitate
persistence of the viral genome; and those involved in lytic
infection, which ultimately leads to host cell destruction and
release of new viruses. The viral proteins expressed shown to
be associated with latent infection include the latency-
associated nuclear antigen (LANA1; ORF 73), viral cyclin
(ORF 72) and viral Fas-associated death domain-like
interleukin 1 gamma-converting enzyme inhibitory protein
(vFLIP; ORF 71), Kaposin A, vIRF1 and LANA2 (Dour-
mishev et al., 2003).
LANA1 (also commonly referred to as LANA) is a large
nuclear antigen detected in the majority of KS lesions as
well as in cell lines derived from BCBLs (Cesarman et al.,
1995a). LANA has a number of functions related to the
transcription and replication of viral episomal DNA and
anchors the circular viral DNA to the host chromatin during
interphase and mitosis. LANA is critical to the persistence of
KSHV episomes and functions in this capacity by tethering
viral episomes to chromosomes during mitosis, which allows
for efficient segregation of viral episomes to daughter cells
(Ballestas et al., 1999; Cotter and Robertson, 1999; Lan et
al., 2004, 2005). In addition, LANA physically interacts with
cellular proteins, including p53 (Friborg et al., 1999), pRB
(Radkov et al., 2000), RING3 (Platt et al., 1999), histone H1
(Cotter and Robertson, 1999; Lan et al., 2004, 2005), ATF4/
CREB2 (Lim et al., 2000), EC5S Ubiquitin Complex (Cai et
al., 2006b) and members of the mSin3 corepressor complex
(Krithivas et al., 2000). Functional consequences of these
interactions include inhibition of p53-mediated apoptosis
(Borah et al., 2004; Friborg et al., 1999), inhibition of the
transcriptional activity of ATF4/CREB2 (Lim et al., 2000),
dysregulation of β-catenin and the Wnt signaling pathway
(Fujimuro et al., 2003), regulation of HIF-1α by inducing
ubiquitination and degradation of VHL and p53 (Cai et al.,
2006a), degradation of the VHL and p53 tumor suppressors
by recruiting the EC5S ubiquitin complex (Cai et al., 2006b)
and in conjunction with Hras, transformation of primary rat
embryonic fibroblasts (Radkov et al., 2000).
The secondary structure of LANA suggests that there are
potential sites for interactions with other cellular factors
involved in transcription (Verma et al., 2007). Its amino acid
sequence indicates that it has an acidic-rich, a proline-rich and a
glutamine-rich domain, a zinc finger DNA binding domain, a
leucine zipper and a potential nuclear localization signal (Verma
et al., 2007). LANA can also repress transcription when fused to
the GAL4 DNA binding domain, tested on a GAL4 responsive
promoter (Verma et al., 2004). LANA tethers the viral genome
through binding to the 13-bp LANA binding sequence (LBS) in
the terminal repeats (TRs) which were identified by overlapping
probes (Cotter et al., 2001). During long-term persistence viral
DNA replicates in a synchronized fashion and segregates to the
daughter cells in a non-random fashion (Verma et al., 2006).
LANA binds to the LANA binding sequence (LBS) through its
carboxy-terminal DNA binding domain (Verma et al., 2006).The amino terminus is important for tethering to the nucleo-
somes, in particular interactions with the histones including
histone H1, and probably with other cellular proteins, which
includes MeCP2 and DEK (Barbera et al., 2006a; Cotter and
Robertson, 1999; Krithivas et al., 2002; Shinohara et al., 2002).
Therefore, LANA appears to be a multifunctional protein
involved in modulating activation and repression of transcrip-
tion. Thus, these activities are likely to be important for
regulation of cell proliferation and apoptosis in KSHV-infected
cells.
To obtain a more comprehensive view of the critical role
for LANA in maintenance of KSHV latency, a list of all
cellular proteins associated with LANA was generated
experimentally through proteomic studies. These results will
provide new insights into the breadth of potential functions
linked to LANA at the molecular level. These include viral
genome maintenance during latency and contribution to cell
proliferation and KSHV-associated pathogenesis. This is a
first step in understanding the complexities of interaction
between host cellular proteins and LANA. Once specific
proteins are identified, characterization of novel LANA
functions will be pursued as the biochemical role of many
of the identified proteins in context of virus infection and
latency remain to be explored. The overall goal of this present
study was to obtain a comprehensive list of cellular proteins
capable of associating with LANA. GST pull-down assays
were used to fractionate protein complexes that interact
specifically with the amino as well as the carboxy-terminal
domains of LANA followed by MALDI-TOF analysis to
identity LANA interacting proteins.
Results and discussion
To determine the identity of cellular proteins interacting
with LANA, we performed pull-down assays with nuclear
extracts from KSHV-positive BC-3 cells. Nuclear extracts
were incubated with Glutathione-conjugated beads bound to
GST fused to the amino terminal domain of LANA and the
carboxy-terminal domain (see Fig. 1) independently.
We hypothesized that protein complexes associated with the
amino and carboxy-termini of LANA would be involved in
tethering, genome maintenance, replication, segregation and
transcriptional regulation can be identified with a proteomic
approach. Results obtained from our pull-down assays,
MALDI-TOF analysis and protein sequencing identified
proteins belonging to about 36 classes of cellular proteins
based on the scheme utilized by the human protein reference
database, copyright® John Hopkins University and the Institute
of Bioinformatics (Mishra et al., 2006; Peri et al., 2003). The
predominant groups identified were DNA binding proteins,
serine/threonine kinases, structural proteins, cytoskeleton
proteins, transcriptional regulatory proteins as well as adapter
and motor proteins all associated with the amino and carboxy-
termini domains of LANA (Table 1a and 1b). Other potentially
important cellular proteins identified include polymerases, cell
cycle control proteins, transcription factors, ubiquitin proteo-
some system regulatory proteins, cytokines, deacetylases and
Fig. 1. GST tagged LANA-amino terminal domain and GST tagged LANA-
carboxy-terminal domain bound on Glutathione–Sepharose beads was used as
bait to pull-down interacting protein from BC3 cell nuclear extract. BC-3
nuclear extract (500 μg) was first pre-cleared with GST only (6 mg) by
incubating at 4 °C for 4 h with rotation. The supernatant was then pre-cleared
with GST-2TK for 2 more hours at 4 °C in similar way. The supernatant from
this step was then incubated with GST–LANA-N at 4 °C overnight. The
beads were washed four times with binding buffer by centrifugation at 4 °C.
The beads were then collected and boiled at 95 °C in SDS–PAGE loading
buffer and run on SDS–PAGE with gel with appropriate controls. Protein
bands unique to LANA pulldown lanes were excised and processed for
MALDI-TOF peptide analysis.
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identified in association with the amino terminal domains of
LANA and 56 proteins were identified associated with the
carboxy-terminal domain of LANA.
A list of identified proteins specifically associated with
the amino terminal of LANA and their functional properties
are shown in Table 1a. Proteins which were deemed
unclassified made up approximately 11%. The largest
group of classified proteins interacting with the amino
terminal domain of LANA were transcriptional factors and
regulatory proteins which made up approximately 11%,
cytoskeletal-associated proteins which accounted for 9% and
structural proteins which made up about 7% of the total
proteins identified. Other important functional group of
proteins interacting with the amino terminus of LANA
included serine/threonine kinases, DNA binding proteins and
cell cycle control proteins (see Table 1a).
An analysis of the cellular proteins interacting with the
carboxy-terminus of LANA showed that the majority of the
proteins belong to five major groups of proteins. These groups
were DNA binding proteins which made up about 19% of the
total proteins, 12% were cytoskeletal or associated proteins,
transcription factors and regulatory proteins made up another
12% of the total, 9% were ribosomal subunits and 5% were
structural proteins (Table 1b). Other groups less prevalent
included transcriptional regulatory proteins, RNA binding
proteins, ribonucleoproteins and ATPases (Table 1b).The five major groups of interacting proteins supported
previous work which showed that LANA had transcription
and DNA binding activities (Groves et al., 2001; Hyun et al.,
2001; Jeong et al., 2001; Knight et al., 2001; Lim et al.,
2001; Renne et al., 2001; Verma et al., 2007). It is interesting
to note that 12% of the proteins associated with the carboxy-
terminal were cytoskeletal proteins and may suggest a
functional role for LANA in association with structural
proteins. This may provide new clues as to the cellular
molecules that are active members of complexes containing
LANA responsible for tethering of the KSHV genome to the
host chromosome.
The data accumulated so far shows 27 specific categories
of proteins associated with the amino terminal domain of
LANA and 25 specific categories for the carboxy-terminal
domain (see Figs. 2 and 3). Overall the total number of
functional categories of proteins involved in LANA associa-
tion was 36 with 16 of these categories of polypeptides
including some identical proteins associating with both the
amino and carboxy-terminal of LANA (see Table 2). Thus,
these results broadly suggest that there may be some interplay
between the amino and carboxy-termini and these two
domains may be involved in similar functions in the context
of KSHV persistence and pathogenesis.
Regulation of cell signaling pathways
Protein kinases control cell signaling events through ATP-
dependent phosphorylation of serine, threonine and tyrosine
residues of the target substrates. The recognition of these
protein substrates by the kinases relies on two principal
factors: proper subcellular colocalization and molecular
interactions between the kinase and substrate (Lieser et al.,
2005). LANA has previously been shown to interact with a
number of cellular kinases including GSK-3β(Fujimuro and
Hayward, 2003, 2004; Fujimuro et al., 2005), an unidentified
kinase in association with RING3 (Mattsson et al., 2002;
Platt et al., 1999) and most recently the Pim-1 kinase (Bajaj
et al., 2006). LANA has also been shown to be critical for
tethering of the viral episome to host cell chromosomes
(Ballestas et al., 1999; Cotter et al., 2001; Krithivas et al.,
2002; Piolot et al., 2001) and is consistently expressed in all
KSHV-positive cells (Kedes et al., 1997). The interaction
with kinases provides LANA with an opportunity to
modulate cell signaling pathways and regulate host gene
expression. Indeed, earlier studies have shown that LANA
can function as a potent transcriptional regulator of both viral
as well as host genes (Friborg et al., 1999; Fujimuro and
Hayward, 2003; Lim et al., 2000, 2001; Radkov et al., 2000;
Renne et al., 2001). In our study, we found four novel
proteins belonging to serine/threonine kinase molecular class
that interacted with LANA. DNA-dependent protein kinase
catalytic subunit (DNA-PKcs) is one of the three subunit that
forms DNA-PK and phosphorylates p53 at serine15 and
serine37 that leads to its activation (Kim et al., 1999). The
major role of DNA-PK is repairing breaks in double stranded
DNA (Collis et al., 2005). Interaction with LANA may
Table 1a
Cellular proteins associated with the amino terminal domain of LANA having a >95% CI score and arranged according to their functional category
Protein functional category Annotation Acession no. kDa/pI Protein score
(CI%)
Ribosomal subunit 39S Ribosomal protein L32 RM32_HUMAN 21/9.78 99.5
40S ribosomal protein S10 RS10_HUMAN 19/10.15 98.9
Serine/threonine kinase DNA-dependent protein kinase catalytic subunit PRKD_HUMAN 468/6.75 100
LIM domain kinase 1 LIK1_HUMAN 72/6.53 99
Protein kinase C, beta type KPCB_HUMAN 77/6.57 97
Adapter molecule SH3 domain-binding protein 2 3BP2_HUMAN 62/7.67 96.5
Homer protein homolog 2 HOM2_HUMAN 40/6.03 95
A-kinase anchor protein 9 AKA9_HUMAN 453/4.95 99.8
Enzyme-oxidoreductase Arachidonate 12-lipoxygenase LOXP_HUMAN 75/5.82 95
Cell cycle control protein CENP-F kinetochore protein CENF_HUMAN 367/5.03 98.8
Cytokine Interferon alpha-1/13 precursor INA1_HUMAN 21/5.32 98.5
Structural protein Spectrin beta chain SPCB_HUMAN 246/5.13 96.9
Lamin A/C LAMA_HUMAN 74/6.57 98.7
Spectrin beta chain SPCB_HUMAN 246/5.13 96.9
Myosin heavy chain MYH8_HUMAN 222/5.59 95
Cytoskeletal-associated protein Vinculin VINC_HUMAN 123/5.51 99.6
Protein 4.1 41_HUMAN 96/5.45 99.9
Bullous pemphigoid antigen 1 isoforms BPA1_HUMAN 371/6.38 99.9
Diaphanous protein homolog 1 DIA1_HUMAN 138/5.31 98.8
Leiomodin 1 LMD1_HUMAN 64/9.51 95
Nesprin 2 SNE2_HUMAN 795/5.26 99.7
Chemokine Small inducible cytokine B14 precursor SZ14_HUMAN 11/9.94 97.4
Transcription factor Zinc finger protein 224 Z224_HUMAN 82/9.03 97.3
Zinc finger protein 255 Z255_HUMAN 72/8.99 97.2
Transcription regulatory protein SET and MYND domain containing protein 1 SMY1_HUMAN 56/6.66 96.8
MAX binding protein MNT MNT_HUMAN 62/8.78 97
SET and MYND domain containing protein 1 SMY1_HUMAN 56/6.66 96.8
Possible global transcription activator SNF2L4 SN24_HUMAN 184/7.65 95.4
Motor protein Myosin XVIIIB M18B_HUMAN 285/6.49 98.1
Ciliary dynein heavy chain 11 DYHB_HUMAN 520/6.03 97.9
Kinesin-like protein KF3C_HUMAN 89/8.45 95
DNA binding protein Synaptonemal complex protein 2 SCP2_HUMAN 175/9.01 99.7
Centromeric protein E CENE_HUMAN 312/5.46 95
Zinc finger protein 179 Z179_HUMAN 68/8.88 95
Chaperon DNAJ homolog subfamily C member 8 DJC8_HUMAN 30/9.15 98.9
Unclassified Nasopharyngeal epithelium specific protein 1 NESG_HUMAN 46/9.99 98.3
MAGUK p55 subfamily member 6 MPP6_HUMAN 61/5.82 99.9
WD-repeat protein 9 WDR9_HUMAN 257/8.68 99.6
Ribosome biogenesis protein BMS1 homolog BMS1_HUMAN 145/6.04 95
Nesprin 1 SNE1_HUMAN 1010/5.38 95
Sperm-specific antigen 2 SSF2_HUMAN 29/4.83 95
Phosphorylase Glycogen phosphorylase, muscle form PHS2_HUMAN 96/6.57 97.8
Thymidine kinase
2, mitochondrial precursor
KITM_HUMAN 31/8.71 95
RNA helicase Putative pre-mRNA splicing factor RNA helicase DD16_HUMAN 119/6.39 98.5
DNA Polymerase DNA polymerase theta DPOQ_HUMAN 197/6.57 95
Cell surface recepter GDNF family receptor alpha 4 precurser GFR4_HUMAN 32/10.47 95
Ubiquitin proteosome system protein F-box only protein 16 FX16_HUMAN 34/10.05 96.6
Intracellular ligand-gated channel Inositol 1.4,5-triphosphate receptor type 3 IP3T_HUMAN 303/6.04 99.6
Phospho-transferase Putative nucleoside diphosphate kinase NDK8_HUMAN 15/8.76 98
Carboxylase Propionyl-CoA carboxylase alpha chain PCCA_HUMAN 77/6.63 96.6
Guanine nucleotide exchange factor Guanine nucleotide exchange factor DBS DBS_HUMAN 123/6.16 99.3
Deacetylase Heparin sulfate N-deacetylase/N-sulfotransferase HSS2_HUMAN 101/8.81 95
Hydroxylase Cytochrome P450 CPS1_HUMAN 56/7.71 95
⁎Protein previously shown to interact LANA.
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results in a block to apoptosis as well as an increase in
chromosomal instability by blocking the DNA repair
mechanism of DNAPK (Someya et al., 2006). Another
LANA interacting kinase is LIM kinase-1 (LIMK1) whichbelongs to a small subfamily of proteins with a unique
combination of 2 amino terminal LIM motifs and a carboxy-
terminal serine only protein kinase domain (Stanyon and
Bernard, 1999). LIMK1 has been found to be overexpressed
in prostate tumors and in prostate cancer cell lines (Davila et
Table 1b
Cellular proteins associated with the carboxy-terminal domain of LANA having a >95% CI score and arranged according to their functional category
Protein functional category Annotation Acession no. kDa/pI Protein score
(CI%)
Serine/threonine kinase Serine/threonine-protein kinase 4 STK4_HUMAN 55/4.97 95
Ribosomal subunit 40S ribosomal protein S11 RS11_HUMAN 18/10.31 99.9
40S ribosomal protein S9 RS9_HUMAN 22/10.66 100
40S ribosomal protein S10 RS10_HUMAN 19/10.15 99
40S ribosomal protein S18 RS18_HUMAN 17/10.99 100
40S ribosomal protein S16 RS16_HUMAN 16/10.21 100
Adapter molecule A-kinase anchor protein 9 AKA9_HUMAN 453/4.95 99.9
Enzyme-Oxidoreductase Myeloperoxidase precursor PERM_HUMAN 83/9.19 99.9
Cytokine Interferon alpha-1/13 precursor INA1_HUMAN 21/5.32 99.4
Cell cycle control protein CENP-F kinetochore protein CENF_HUMAN 367/5.03 99.3
Diablo homolog, mitochondrial precursor DBOH_HUMAN 27/5.68 99.1
Structural protein Myosin heavy chain, skeletal muscle, fetal MYH4_HUMAN 222/5.67 98.9
Myosin heavy chain,
cardiac muscle beta isoform
MYH7_HUMAN 222/5.63 98.5
Nuclear mitotic apparatus protein 1 NUMA_HUMAN 238/5.63 95
Cytoskeletal-associated
protein
Src substrate cortactin SRC8_HUMAN 61/5.24 99.7
Tropomyosin 1 alpha chain TPM1_HUMAN 32/4.69 97.1
Nebulette NEBL_HUMAN 116/7.89 96.9
Cytoskeletal protein Merlin MERL_HUMAN 69/6.11 95
Moesin MOES_HUMAN 67/6.09 97.8
Periplakin PEPL_HUMAN 204/5.44 96.6
Nebulin NEBU_HUMANHSS2_HUMAN 772/9.1 97.9
Chemokine Phosphatidylinositol 3-kinase
regulatory gamma subunit
P55G_HUMAN 54/5.75 99.7
Transcription factor General transcription factor 3C polypeptide 1 T3C1_HUMAN 238/7.03 95
Possible global transcription activator SNF2L4 SN24_HUMAN 184/7.65 95.4
Homeobox protein TGIF2LY TGLY_HUMAN 20/9.84 97.3
ATP-dependent RNA helicase A DD16_HUMAN 119/6.39 99
Transcription regulatory
protein
RNA polymerase II transcription
factor SIII subunit A2
ELA2_HUMAN 84/9.76 95
Possible global transcription activator SNF2L1 SN21_HUMAN 114/8.72 97.5
Thyroid hormone receptor-associated
protein complex 150 kDa component
T150_HUMAN 150/xx 95
Motor protein Ciliary dynein heavy chain 11 DYHB_HUMAN 520/6.03 97.9
Unclassified Nasopharyngeal epithelium specific protein 1 NESG_HUMAN 46/9.99 99.9
DNA binding protein Synaptonemal complex protein 1 HSS2_HUMAN 113/5.85 95.9
Centromeric protein E CENE_HUMAN 311/5.46 98.7
Histone H3.4 H3T_HUMAN 15/11.13 100
Histone H3.3 H33_HUMAN 15/11.27 100
Histone H2B type 12 H2BX_HUMAN 13/10.32 100
Histone H2A.e a H2AE_HUMAN 13/10.88 100
Histone H2A.qa H2AQ_HUMAN 13/10.90 100
Histone H2B.ba H2BB_HUMAN 13/10.32 100
Histone H2A.la H2AL_HUMAN 14/11.05 100
Histone H2A.ga H2AG_HUMAN 14/10.9 100
Methyl-CpG-binding protein 2a MBD2_HUMAN 43/xx 95
Chaperon Nucleophosmin NPM_HUMAN 32/4.64 100
ATPase Putative pre-mRNA splicing
factor RNA helicase
DD16_HUMAN 119/6.39 98.5
RNA Binding protein Splicing factor, arginine/serine-rich 3 SFR3_HUMAN 19/11.64 99.3
GTPase activating protein 1-phosphatidylinositol-4,
5-bisphosphate phosphodiesterase beta 4
PIB4_HUMAN 134/6.47 95
GTPase Dynamin-like 120 kDa protein OPA1_HUMAN 111/7.88 99.1
Nucleolar GTP-binding protein 1 NOG1_HUMAN 74/xx 95
Anchor protein Kinectin KTN1_HUMAN 156/5.52 99.4
Plectin 1 PLE1_HUMAN 531/5.73 97.5
Ribonucleoprotein Heterogeneous nuclear ribonucleoprotein M ROM_HUMAN 77/8.94 96.6
MHC Complex protein SET protein SET_HUMAN 33/4.23 99.9
Transport/cargo protein ATP-binding cassette sub-family E member 1 ABE1_HUMAN 67/8.63 99
Topoisomerase DNA topoisomerase II, alpha isozymea TP2A_HUMAN 174/xx 95
DNA topoisomerase I TOP1_CRIGR 90/xx 95
a Protein previously shown to interact LANA.
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Fig. 2. Proportional distribution of LANA-amino terminal interacting proteins in classes based on their functions. The proteins have been classified based on their
molecular function as per the scheme followed by Human protein reference database Copyright Johns Hopkins University and the Institute of Bioinformatics.
322 R. Kaul et al. / Virology 364 (2007) 317–329al., 2003). The interaction of LANA with kinases suggests a
process which may provide an explanation for the mechan-
ism by which LANA might be regulating host cell regulatory
pathways and cell fate decisions. It is quite possible that
interaction with LANA might interfere with the kinase
activity of these proteins leading to a cascade of events. This
results in enhancement of the tumorigenic phenotype or a
blockade of apoptotic pathways.
A potential role for LANA in cell division
DNA-binding proteins include various transcription factors,
nucleases and histones which are involved in DNA packaging in
the cell nucleus. Since one of the primary roles of LANA is the
tethering of KSHV episome to the host cell chromatin and that
LANA itself is a DNA binding protein (Groves et al., 2001;Fig. 3. Proportional distribution of LANA-carboxy-terminal interacting proteins in c
molecular function as per the scheme followed by Human protein reference databasHyun et al., 2001; Jeong et al., 2001; Knight et al., 2001; Lim et
al., 2001; Renne et al., 2001; Verma et al., 2007), it is highly
probable that other DNA binding proteins might interact with
LANA either directly or indirectly through association with
LANA bound to DNA. One of the proteins identified in our
study associated with LANA in our pull-down assay was the
centromeric protein E (CENP-E) (Table 1). CENP-E has been
reported to be essential for stable, bi-oriented attachment of
chromosomes to spindle microtubules, for development of
tension across aligned chromosomes, for stabilization of spindle
poles and for satisfying the mitotic checkpoint (Yao et al., 2000).
This interaction might suggests a role for LANA in ensuring
efficient genomic replication during mitosis and later distribu-
tion of KSHV episomes to daughter nuclei through interaction
with DNA binding proteins like CENP-E which is involved in
spindle attachment (Yao et al., 2000).lasses based on their functions. The proteins have been classified based on their
e Copyright Johns Hopkins University and the Institute of Bioinformatics.
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As obligatory intracellular parasites, viruses need a host cell
to keep dividing to enable them to propagate. Herpesviruses,
however, can survive in host cells for prolonged duration by
virtue of their ability to remain latent and avoid detection by
host immune responses and expression of a limited set of
genes (Minarovits, 2006). When the host is immuno-
compromised the virus can reactivate from latent infection
and ultimately lead to an increase in viral load and subsequent
development of lymphoproliferative disease (Cesarman and
Mesri, 2007). One of the categories of proteins that might
play an important role in modulating this process is the cell
cycle regulatory proteins. In the present study, we found that
the KSHV latent protein LANA interacts with Mitosin/CENP-
F which belongs to this class of regulatory proteins (Table 1).
CENP-F is a large nuclear/kinetochore protein which contains
multiple leucine zipper motifs important for protein–protein
interactions. Its expression levels and subcellular localization
patterns are regulated in a cell cycle-dependent manner (Feng
et al., 2006). Recently, accumulating lines of evidence have
suggested that it is a multifunctional protein involved in
mitotic control, microtubule dynamics, transcriptional regula-
tion and muscle cell differentiation (Ma et al., 2006). Thus, its
interaction with LANA suggests a role for LANA in
regulating these associated processes.
The role of LANA in transcription regulation
The regulation of host gene expression is an important aspect
of the life cycle of KSHV that enables it to persist, replicate and
propagate its genome into new cells. The most common
mechanism is by regulating the transcription of host cell genes
involved in cell fate decisions. LANA has previously been
shown to be a potent transcriptional regulator of both viral as
well as host cell genes (Friborg et al., 1999; Fujimuro and
Hayward, 2003; Lim et al., 2000, 2001; Radkov et al., 2000;
Renne et al., 2001). LANA is known to activate as wells as
repress transcription (An et al., 2002; Groves et al., 2001; Hyun
et al., 2001; Jeong et al., 2001; Knight et al., 2001; Lim et al.,
2001; Renne et al., 2001). A look at the secondary structure of
LANA suggests that there are potential sites for interactions
with other cellular factors involved in transcription (Cotter et
al., 1999). In addition, our study suggested that LANA may
directly interact with a number of host transcriptional factors
and transcription regulatory proteins (Table 1). These include
the zinc finger protein 224, nucleoside diphosphate kinase B,
MAX binding protein MNT (ROX protein), Sp110 nuclear
body protein, SSX5 protein and SET and MYND domain
containing protein 1 (see Table 1). The zinc finger protein 224
has been shown to contain a repressor domain and act as a
transcriptional repressor (Lee et al., 2002). Interestingly, LANA
also binds to MNT which when complexes with MAX and is
known to repress transcription of E box promoters (Cvekl et al.,
2004; Hurlin et al., 1997) and can function as a possible tumor
suppressor gene in this context (Cvekl et al., 2004). On the other
hand, Nm23-H2 has been shown to function as a transcriptionalactivator of the translocated c-Myc allele in Burkitt's lymphoma
(Ji et al., 1995). SP110 is the closest human homolog of the
mice Ipr1 gene which has been speculated to function in
integrating signals generated by intracellular pathogens with
mechanisms controlling innate immunity, cell death and
pathogenesis (Pan et al., 2005). SSX5 is also a cancer-related
protein whose expression has been shown to correlate with
adverse prognosis in multiple myeloma patients (Taylor et al.,
2005). The carboxy-terminal of LANA also was able to pull-
down transcription factors including the Transcription factor
IIIC (TFIIIC) which is a general RNA polymerase III
transcription factor (Shen et al., 1996). The interaction of
LANA with different transcription factors and regulators
strongly suggest a potential role for LANA in dysregulating
genes that are involved in tumorigenesis or tumor suppression.
Moreover, a large number of the transcription factors and
regulators were shown to interact with the amino terminal
domain of LANA. The amino terminus of LANA has been
shown to bind to the chromosomal linker protein histone H1 and
thus contributing to tethering of the KSHV genome to host cell
chromosomes (Cotter and Robertson, 1999; Verma and
Robertson, 2003). Our results suggest that the amino terminal
domain of LANA may play a major role in transcriptional
regulation of other genes when compared to the carboxy-
terminal domain. In fact these two domains may cooperate with
each other by contributing to the transcription regulation of
specific cellular genes.
Cytoskeleton proteins associate with LANA
LANA is critical for the establishment of latent KSHV
infection through maintenance of the viral episome (Ballestas et
al., 1999; Ballestas and Kaye, 2001; Moorman et al., 2003;
Piolot et al., 2001). LANA also tethers the KSHV genome to
host cell chromosome (Cotter and Robertson, 1999; Verma and
Robertson, 2003). It is also believed that the KSHV genome
persists as chromatin in latently infected cells. Therefore, it is
not surprising that LANA interacts with several DNA binding
proteins including histones (Barbera et al., 2006a, 2006b; Cotter
and Robertson, 1999; Shinohara et al., 2002). Our assays also
showed the binding of LANA to several structural proteins and
cytoskeletal-associated proteins (see Table 1). Interestingly, one
such protein was identified as the centrosomal protein Cep290
which contains a series of coiled-coil domains important for
association with the centrosomes and may reflect a role for
LANA in regulation of cell shape, polarity, motility and cell
division through its effects on the mitotic spindle apparatus
(Warby, 2006).
Uncategorized proteins associated with LANA
Other proteins of interest bound to the amino terminal
domain of LANA include a putative RNA helicase (MOV10),
the theta subunit of DNA polymerase, a phosphotransferase
(NDP kinase), a Guanine nucleotide exchange factor (DBL's
big sister) and a cell cycle control protein (Centromere
protein F) (see Table 1a). The carboxy-terminus of LANA
Table 2
Comparison of proteome complex composition at amino and carboxy-termini of
LANA
Protein category Carboxy-terminal Amino terminal
No. of
proteins
identified
Proportion No. of
proteins
identified
Proportion
1 ATPase 1 2% None NAa
2 RNA binding protein 1 2% None NA
3 GTPase activating
protein
1 2% None NA
4 GTPase 2 3% None NA
5 Anchor protein 2 3% None NA
6 Ribonucleoprotein 1 2% None NA
7 MHC Complex
protein
1 2% None NA
8 Transport/cargo
protein
1 3% None NA
9 Topoisomerase 2 3% None NA
10 Ribosomal Subunit 5 9% 2 4%
11 Adapter molecule 1 2% 3 6%
12 Enzyme-
oxidoreductase
1 2% 1 2%
13 Cytokine 1 2% 1 2%
14 Cell cycle control
protein
2 3% 1 2%
15 Structural Protein 3 5% 4 7%
16 Cytoskeletal-
associated protein
3 5% 5 9%
17 Cytoskeletal protein 4 7% 1 2%
18 Chemokine 1 2% 1 2%
19 Transcription factor 4 7% 2 4%
20 Serine/threonine
kinase
1 2% 3 6%
21 Transcription
regulatory protein
3 5% 4 7%
22 Motor protein 1 2% 3 6%
23 Unclassified 1 2% 6 11%
24 DNA binding protein 11 19% 3 6%
25 Chaperon 1 2% 1 2%
26 Phosphorylase None NA 2 4%
27 RNA helicase None NA 1 2%
28 DNA polymerase None NA 1 2%
29 Enzyme-hydroxylase None NA 1 2%
30 Cell surface receptor None NA 1 2%
31 Ubiquitin proteasome
system protein
None NA 1 2%
32 Intracellular ligand-gated
channel
None NA 1 2%
33 Enzyme:
phosphotransferase
None NA 1 2%
34 Carboxylase None NA 1 2%
35 Guanine nucleotide
exchange factor
None NA 1 2%
36 Enzyme: deacetylase None NA 1 2%
Total 55 53
a NA: not applicable.
324 R. Kaul et al. / Virology 364 (2007) 317–329also showed interactions with an ATPase (ATP-dependent
RNA helicase), an RNA binding protein (pre-mRNA splicing
factor SRP20), a GTPase activating protein and a GTPase
(see Table 1b). The identification of these proteins also
provides some insights into the potential additional roles for
LANA in a range of distinct multiple cellular processes that
are yet to be explored.The amino and carboxy-termini of LANA interact with
CENP-F and can from a complex with each other in vitro
Analysis of the amino acid sequence of LANA reveals
three major protein domains. These include the amino terminal
domain, the central domain and the carboxy-terminal domain
(Verma et al., 2004). On comparing the proteins interacting
with the amino terminus of LANA with those seen with the
carboxy-terminus of LANA, we noticed that several of the
host cell proteins showed interaction with both the carboxy
and amino termini of LANA (see Table 2). One of the most
prominent of such proteins was the Centromeric proteins
CENP-E and CENP-F as well as another DNA binding protein
the synaptonemal complex protein 2 (SCP-2 protein) (Tables
1a and 1b). We hypothesized that the amino and carboxy-
termini of LANA might be folded in such a way as to facilitate
their interaction with these common interacting proteins and
possibly with each other. To test this hypothesis, we first
validated the interaction of CENP-F with full-length LANA.
CENP-F was identified in association with both the amino and
carboxy-termini of LANA. Cell lysates prepared from 293 T
cells transfected with Myc-tagged LANA or PA3M vector
alone control were incubated with anti-CENP-F antibody after
pre-clearing with matched immunoglobulin G control anti-
body. The immune complexes were precipitated using a
mixture of protein A+G beads and then probed with anti-Myc
antibody in western blot. The results of these experiments
showed that LANA can coimmunoprecipitate complexes
which contained CENP-F when expressed in human epithelial
cells (Fig. 4a, top panel).
To further support the potential associations of CENP-F
with LANA, we investigated the localization of LANA and
CENP-F in normal and G2/M phase arrested BCBL-1 cells by
immunofluorescence assay. Localization of LANA using rabbit
anti-LANA antibody visualized by Alexa Fluor 594 showed
the characteristic punctate pattern of LANA in the nuclei of
BCBL-1 cells (Fig. 4, see panel b) as reported previously
(Ballestas et al., 1999; Cotter and Robertson, 1999). CENP-F
expression is regulated by the cell cycle, reaching maximum
levels in G2/M, followed by rapid degradation after mitosis
(Liao et al., 1995; Zhu et al., 1995). Therefore, we blocked the
BCBL-1 cells at the G2/M phase by nocadozole treatment.
This resulted in the majority of cells been blocked in G2/M
phase (Fig. 4). As cells progress through G2, CENP-F begins
to localize around the nuclear boundary (Fig. 4, panels c and
d). CENP-F was detected by mouse primary anti-CENP-F
antibody and detected by Alexa Fluor 488 secondary antibody
showed nuclear staining (Fig. 4). These results suggest that
LANA is present in compartments similar to that of CENP-F in
KSHV-positive cells. This occurs in G2 phase of the cell cycle
when CENP-F is expressed at its maximum level and is
localized in nuclear matrix (Fig. 4). The specificity of the
signals was confirmed by incubating the cells with control
immunoglobulin G and Alexa Fluor secondary antibodies
which showed no specific signals (data not shown). Thus, these
colocalization data strongly suggest that LANA associates with
CENP-F during the G2 phase of the cell cycle when the
Fig. 4. CENP-F interacts with LANA. 293 T were transected with LANA-Myc expressing construct and harvested after 24 h. CENP-F was immuno-precipitated
from the cell lysate using specific antibody and then probed for coimmunoprecipitated LANA with anti-Myc antibody. Anti-p53 antibody was used as positive
control to coimmunoprecipitate LANA and normal goat serum was used as non-specific antibody control. Lane 2 (Fig. 5a, top panel) shows the
coimmunoprecipated LANA compared to 10% input in lane 1. Lane 3 shows the coimmunoprecipitated LANA along with p53 as positive control. Bottom panel
(Fig. 5a) shows the same membrane reprobed with CENP-F antibody. The immunofluoroscence assay was done to visualize the localization of LANA (nuclear)
and CENP-F (nuclear membrane) in KSHV-positive BCBL-1 cells. The cells were blocked in G2/M phase by nocadozole treatmen (Fig. 5b, panel c shows the
localization of CENP-F in nuclear matrix partially colocalizing with LANA. Panel d shows a cell in late G2 phase with CENP-F localizing mainly around nuclear
envelope.
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localization is diffused within the nuclear matrix.
To confirm whether or not the carboxy and amino termini
of LANA can interact with each other, we performed in vitro
binding assays with GST fusion proteins of LANA-amino
terminus with in vitro translated LANA-carboxy-terminus.
The binding data demonstrated that the amino terminus of
LANA do directly interact with the carboxy-terminus of
LANA (Fig. 5). When the results were quantified using Image
Quant analysis, the binding activity suggested a greater than
10% binding affinity based on a comparison with input
protein.
MALDI-TOF approach for identification of proteins
interacting with LANA
The application of MALDI-TOF based peptide analysis to
identify LANA-associated proteins from nuclear extract wasable to identify a number of known LANA interacting proteins
and has significantly expanded the number and categories of
proteins which interact with the Kaposi sarcoma-associated
latent nuclear antigen. A large number of proteins were
identified that have potentially important roles in KSHV
latency, specifically the DNA polymerase theta and DNA-
PKcs. LANA therefore forms complexes with proteins belong-
ing to several defined functional classes. This expanded view of
cellular interacting proteins suggests new cellular functional
areas that may be involved in KSHV biology. Further
examination of the coupling of some of the identified proteins
to LANA function or KSHV latency, by overexpression or by
specific knock down of individual proteins using siRNA, may
identify drug targets for KSHV-associated diseases. The
fingerprint of interacting partners derived in this study may be
useful for further comparisons, for example between the KSHV
LANA and other gammaherpesvirus latent proteins (Acker-
mann, 2006) or to examine the relation between differences in
Fig. 5. LANA-amino terminus interacts with LANA-carboxy-terminal doamin.
GST tagged LANA-amino domain (aa 1–340) protein was incubated with in
vitro translated LANA-carboxy-terminus labeled with 35S-methionine. LANA-
carboxy domain showed binding to the amino terminal domain (lower panel,
lane 5) but not to GST control (Lower panel, lane 4). The Coomassie-stained gel
with GST–LANA-amino terminus is shown in the upper panel.
326 R. Kaul et al. / Virology 364 (2007) 317–329function and changes in complexes with cellular interacting
proteins.
Materials and methods
Cell lines and plasmids
KSHV-positive cell line BC-3 was cultured in RPMI 1640
medium supplemented with 7% fetal bovine serum (FBS),
2 mM L-glutamine and 25 U/ml of penicillin–streptomycin.
This cell line was grown at 37 °C in a humidified chamber
supplemented with 5% CO2. The carboxy-terminal domain (945
to 1162 aa) and amino terminal domain (1–340 aa) constructs
tagged with GST were prepared by PCR amplification of
fragment from PA3M-LANA followed by cloning into pGEX-
2TK vector within BamHI and EcoRI restriction sites.
Preparation of GST fusion proteins for in vitro binding assays
Escherichia coli BL-21 cells were transformed with plasmid
constructs for each fusion protein, and single colonies were
picked and grown overnight in 2 ml of Luria–Bertani (LB)
medium. Five hundred milliliters of LB medium was inoculated
at a dilution of 1:200 and allowed to shake at 37 °C until the
mid-exponential growth phase. Cells were then induced with
1 mM IPTG (isopropyl-β-D-thiogalactopyranoside) for 4 h with
continuous shaking at 37 °C. Cells were harvested and
sonicated, and the proteins were solubilized in the presence of
protease inhibitors. Solubilized proteins were incubated with
Glutathione S-transferase (GST)–Sepharose beads for 6 h or
overnight at 4 °C with rotation and then collected by
centrifugation and washed three times in NETN buffer with
protease inhibitors. GST fusion proteins bound to beads were
used for binding assays and stored in NETN buffer with
protease inhibitors and 1 mM phenylmethylsulfonyl fluoride at
4 °C.Preparation of nuclear extract from KSHV-positive (BC3) cells
To isolate nuclear proteins binding with LANA-amino and
LANA-carboxy-terminal domains, nuclear extract was prepared
from BC-3 cells. BC-3 cells are B cells latently infected with
KSHV (Cesarman et al., 1995b) expressing LANA. Therefore,
these cells are expected to express large amount of LANA
interacting proteins. The nuclear extract was prepared to enrich
for low abundance proteins and to overcome the low sensitivity
of experimental setup that involves manual excision of single
protein bands from SDS–PAGE. Briefly, 1000×106 cells were
harvested, washed with cold PBS, resuspended in buffer A
(10 mM HEPES, 10 mM KCl, 1.5 mM MgCl2, 5 mM DTT and
protease inhibitors), incubated on ice for 1 h. These were then
homogenized in douncer and the extracted nuclei were
separated by centrifugation at low speed. Nuclei were then
lysed by resuspending in Buffer B (20 mM HEPES, 10%
glycerol, 420 mM NaCl, 1.5 mM MgCl2, 5 mM DTT and
protease inhibitors) for 30 min. Nuclear membrane debris was
removed by high speed centrifugation and supernatant contain-
ing nuclear proteins was mixed with equal volume of buffer C
(20 mM HEPES, 30% glycerol, 1.5 mM MgCl2, 0.2 mM
EDTA, 5 mM DTT and protease inhibitors). The protein
concentration was determined by Bradford assay and the
nuclear extract was stored at −80 °C.
GST-fusion pull-down assay for identification of LANA
interacting proteins
BC-3 nuclear extract (500 μg) was first pre-cleared with GST
only (6 mg) by incubating at 4 °C for 4 h with rotation. The
supernatant was then pre-cleared with GST-2TK for 2 more
hours at 4 °C in similar way. The supernatant from this step was
then incubated with GST–LANA-C or GST–LANA-N at 4 °C
overnight. The beads were washed four times with binding
buffer at 4 °C. The beads were then collected and boiled at
95 °C in SDS–PAGE loading buffer and run on SDS–PAGE
with gel with appropriate controls.
In vitro binding of LANA-amino to LANA carboxy-terminal
proteins
LANA-carboxy-terminal was expressed in vitro by the coupled
in vitro transcription/translation system (TNT) of Promega Inc.
(Madison, WI) according to the manufacturer's instructions, using
[35S]methionine/cysteine (Perkin Elmer Inc., Boston, MA) in the
TNT reaction mixture. LANA-N-GST fusion protein (approxi-
mately 10 μg for each reaction), expressed in E. coli were used for
in vitro bindings. In-vitro-translated proteins were pre-cleared with
Glutathione–Sepharose beads in binding buffer (1× phosphate-
buffered saline, 0.1% NP-40, 0.5 mM dithiothreitol, 10% glycerol,
1 mM phenylmethylsulfonyl fluoride, 2 μg of aprotinin per ml) for
30 min. Pre-cleared labeled protein were then incubated with
either GST or GST–LANA-amino fusion proteins in binding
buffer. Binding was performed overnight at 4 °C with constant
rotation followed by centrifugation for collecting the beads. The
beads were washed three times with 1 ml of binding buffer
327R. Kaul et al. / Virology 364 (2007) 317–329followed by resuspending them in SDS lysis buffer and resolving
them on SDS–PAGE. The bound fraction was analyzed after
drying the gel and exposing to a phosphorImager plate (Molecular
Dynamics, Inc.).
Protein isolation and mass spectroscopy
Visible protein bands between 18 to>204 kDa size that were
unique to the GST–LANA-N or GST–LANA-C pull-down
lanes were cut out of the Coomassie-stained gel and in-gel
digestion conducted with sequencing grade trypsin. The excised
gel pieces were then washed with 100 μl of 50 mM ammonium
bicarbonate in 50% acetonitrile. They were then shrunk by
dehydration in acetonitrile followed by solvent removal in a
vacuum centrifuge. They were swollen in 100 μl of a digestion
buffer containing 50 mM ammonium bicarbonate, 5 mM
calcium chloride (50 μl), and 12.5 ng/ml of trypsin and
enzymatic cleavage was allowed to continue overnight at 37 °C.
Peptides were extracted into 20 mM ammonium bicarbonate
(100 μl) followed by two separate extractions into 100 μl of
water/acetonitrite/formic acid (10:10:1, v/v/v). After evapora-
tion to dryness, peptides were redissolved in 10 μl of 5%
acetonitrile and 0.1% trifluoroacetic acid.
One portion (1/10) of the digest was analyzed directly by
matrix-assisted laser desorption/ionization-TOF mass spectro-
scopy for molecular weight determination and matrix-assisted
laser desorption/ionization-TOF/TOF for sequence information
(Applied Biosystems, Foster City, CA). The other portion (1/3)
was subjected to nanoLC/Qstar-XL (Applied Biosystems,
Foster City, CA) analysis. The data were analyzed with GPS
explorer (for TOF-TOF) or Analyst QS (for Qstar) software
(Applied Biosystems, Foster City, CA) and were searched with
Mascot software (Matrix Science Ltd., London, UK) against the
National Center for Biotechnology Information database. The
proteins with CI% score above 95 were selected for analysis.
Immunoprecipitation and Western blotting
After 48 h of incubation, the transfected cells were lysed in
cold radioimmunoprecipitation assay buffer (50 mM Tris [pH
7.6], 150 mM NaCl, 2 mM EDTA, 1% Nonidet P-40, 1 mM
phenylmethylsulfonyl fluoride, aprotinin [1 μg/ml] and pep-
statin [1 μg/ml]) on ice and homogenized. The lysates were pre-
cleared with Protein A/G–Sepharose beads (Amersham Bios-
ciences Inc., Piscataway, NJ) and then incubated first with
antibodies against myc (1 μg) in immunoprecipitation (IP)
buffer (20 mM Tris–HCl, pH 8.0, 10% glycerol, 5 mM MgCl2,
0.1% Tween 20, 0.1 M KCl, 1× protease inhibitor cocktail
[Amersham Biosciences Inc., Piscataway, NJ] and 0.5 mM
dithiothreitol) overnight at 4 °C with constant rotation and then
with Protein A/G (50/50)–Sepharose beads for 1 h. Beads were
washed three times with IP buffer and resuspended in 40 μl of
2× sodium dodecyl sulfate Laemmli buffer. The sample was
subjected to sodium dodecyl sulfate–polyacrylamide gel
electrophoresis. Western blot analyses were performed using
primary monoclonal antibodies against myc (9E10) and β-actin
(Santa Cruz Biotechnology Inc., Santa Cruz, CA). Detectionand quantification were done using a Li-Cor Odyssey scanner
(Li-Cor, Inc., Lincoln, NE).
Immunofluorescence assays
Nocadozole treated BCBL1 cells were washed with PBS and
spread evenly on a slide. The cells were fixed with 1:1
methanol–acetone for 10 min at −20 °C, dried and rehydrated
with PBS. For blocking, cells were incubated with PBS
containing 3% bovine serum albumin and 1% glycine for
30 min. Cells were then incubated with appropriate antibodies
(1:100 dilution of anti-CENPF antibody and a 1:100 dilution of
anti-LANA antibody). Slides were washed three times in
phosphate-buffered saline and further incubated with a 1:1,000
dilution of goat anti-rabbit or goat anti-mouse immunoglobulin-
fluorescein isothiocyanate-conjugated secondary antibodies.
Slides were examined with an Olympus IX70 fluorescence
microscope, and images were captured with a PixelFly digital
camera (Cooke, Inc., Auburn Hills, MI).
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